Latest news
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - simplywall.stsimplywall.st · Sat, 08 Aug 2026 03:06:16 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingViewTradingView · Fri, 07 Aug 2026 18:31:00 GMTDenali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 22:45:12 GMTDenali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 21:40:05 GMTDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:01:33 GMTDenali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:14:03 GMTDenali Therapeutics reports $3.6M in Q2 2026 product revenue, pro forma cash >$1.1B - TradingViewTradingView · Thu, 06 Aug 2026 20:13:22 GMTDenali Therapeutics Inc. 2026: Revenue $3.6M, EPS ($0.68) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:11:01 GMT